Stockreport

Compass Therapeutics: Potential Here, But Patience Required [Seeking Alpha]

Compass Therapeutics, Inc.  (CMPX) 
PDF Tovecimig achieved a 17% ORR in 2L BTC, outperforming chemo alone and positioning CMPX for a potential $1B+ market opportunity if approved. Pipeline assets CTX-471 an [Read more]